RxDoctor Payments Data

Monica Luthra, DO

Internal Medicine · Snyder, NYNPI 1245692516

Payments from drug & device makers

$6,543in general payments, 2019–2025

Across 361 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$698
  • Lilly USA, LLC$658
  • Amgen$608
  • Esperion Therapeutics, Inc.$546
  • Boehringer Ingelheim$468
  • AstraZeneca$441
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$6,45399%
  • Education$901%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,543 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$67,418
Medicare patients
110
Services billed
739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide295$388,799
MounjaroTirzepatide212$270,162
EliquisApixaban105$145,652
Trelegy ElliptaFluticasone/Umeclidin/Vilanter159$133,068
Repatha SureclickEvolocumab97$113,869
RybelsusSemaglutide44$98,259
JardianceEmpagliflozin65$95,921
TrulicityDulaglutide31$55,775
XareltoRivaroxaban30$37,216
EntrestoSacubitril/Valsartan29$36,546
Repatha SyringeEvolocumab14$19,139
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$18,036
VascepaIcosapent Ethyl24$17,998
FarxigaDapagliflozin Propanediol11$16,687
LinzessLinaclotide11$12,913

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$698$487,057339 claims
Lilly USA, LLCMounjaro, Trulicity$658$325,937243 claims
PfizerEliquis$262$145,652105 claims
GSKTrelegy Ellipta$287$133,068159 claims
Boehringer IngelheimJardiance$468$95,92165 claims
Johnson & JohnsonXarelto$155$37,21630 claims
NovartisEntresto$216$36,54629 claims
AstraZenecaBreztri Aerosphere, Farxiga$441$34,72334 claims
AbbVieLinzess, Synthroid$145$14,91845 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$16$6,195345 claims
ANI Pharmaceuticals, Inc.Valsartan$52$3,138120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Snyder

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →